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F O R E W O R D
There has been a growing interest in the marine derived bioactivecompounds in the recent years, and the functional foods, enriched
with natural ingredients have been proved to provide beneficial action
for human health. Marine derived bioactive components and the functional food ingredients
demonstrated to possess potential health benefits. High value secondary bioactive
metabolites from the marine organisms are attracting attention because of the growing
demand for new compounds of 'marine natural' origin, having potential applications in
pharmaceutical fields, and concerns about the adverse effects by synthetic drugs and their
derivatives. The pioneering R & D works at ICAR-Central Marine Fisheries Research Institute
on marine bioprospecting envisaged a systematic approach involving chemical profiling of
major species of marine organisms for bioactive pharmacophore leads for activity against
various diseases, and a library of molecules with bioactive potential. The research work in
this institute developed protocols to prepare various pharmaceutical leads, nutraceuticals/
functional food supplements enriched with lead molecules with different properties against
various drug targets for use against various life-threatening diseases.
ICAR-Central Marine Fisheries Research Institute is the pioneering marine research
institute in India to work in the frontier area of bioactive molecule discovery from marine
organisms as promising therapeutic agents against various diseases, aquatic food product
technology, and development of high value products for health management. This prestigious
research institute of Indian Council of Agricultural Research is working in the broad national
interest of producing high value bioactive leads from the marine organisms, which would
provide promising therapeutic agents against various diseases. This institute has developed
and commercialized the nutraceutical products CadalminTM Green Algal extract (CadalminTM
GAe) and Antidiabetic extract (CadalminTM ADe) as green alternatives to synthetic drugs to
combat rheumatic arthritic pains and type-2 diabetes, respectively to a leading
biopharmaceutical company in India. The anti-inflammatory nutraceutical Cadalmin™ Green
Mussel extract (Cadalmin™ GMe) from Asian green mussel Perna viridis has been
commercialized with Amalgam Group of Companies. CadalminTM Antihypercholesterolemic
extract (CadalminTM ACe) has been developed from seaweeds to combat dyslipidemia leading
to obesity, and the product was out-licensed to a leading Indian MNC in wellness and
obesity management. Antimicrobial therapeutic product from marine bacteria as oral
applicant has been developed and the product is in pipeline for commercialization. Seaweed-
derived natural template inspired synthetic derivatives as potential pharmacophores were
designed and developed. Several nutraceutical and cosmeceutical products from marine
organisms are in pipeline, and are being commercialized.
The objective of the National level ICAR Winter School on "Recent advances in bioactive
compounds from marine organisms and development of high-value products for health
management" is to provide up-to-date information and acquaint the participants with the
latest technologies on isolation and characterization of marine natural products of
pharmaceutical importance from marine organisms, general and advanced methods of
isolation procedures by chromatography, classification of organic compounds and their
characterization by advanced spectroscopic experiments. This program further aims to give
exposure to the chemical perspectives of marine organisms, primary and secondary bioactive
metabolites from fish and marine organisms to develop bioactive compounds and high-
value functional food products. Theory and practical classes will be conducted in these
areas to provide the participants a hands-on experience.
This ICAR Winter School is organized with the full funding support from ICAR, New
Delhi, and the twenty-five participants from various parts of India who are attending this
programme were selected after scrutiny of their applications based on their bio-data. They
are serving as academicians, such as Professors/Scientists, and in similar posts. The faculties
include the knowledgeable scientists and professors from various parts of India and abroad.
This training will enable the participants to efficiently carry out their academic programmes,
and to plan research on bioactive molecule discovery in their respective laboratories and
institutes so that they can formulate the strategies for research.
The Winter School on "Recent advances in bioactive compounds from marine organisms
and development of high value products for health management" is very ideal for the
current scenario of increasing lifestyle diseases and human health. Understanding the
importance of natural products in the health care system of India, ICAR-Central Marine
Fisheries Research Institute has reasonably contributed in the various aspects. The Manual
released on this occasion covers all aspects of marine natural products prepared by the
experts in their respective fields. I congratulate the Course Director of this programme, Dr.
Kajal Chakraborty and Head of the Marine Biotechnology Division, Dr. P. Vijayagopal, along
with other staff members of Marine Biotechnology Division and Central Marine Fisheries
Research Institute for their sincere efforts in bringing out the manual in time, and to arrange
the programme in a befitting manner.
A. Gopalakrishnan
Director, ICAR-Central Marine Fisheries Research Institute
Kochi, Kerala
P R E F A C E
Marine-derived bioactive components and the functional food ingredients with potentialhealth benefits are an emerging area of research. The rich diversity of flora and fauna
in the marine and coastal habitats of the Indian subcontinent represent an untapped reservoir
of bioactive compounds with valuable pharmaceutical and biomedical use. Considering the
underutilization of these groups of marine organisms, exploring bioactive compounds and
development of any biologically useful products have benefits as health products.
Comprehensive analyses demonstrated that during the last decade the average proportion
of bioactive compounds among the new compounds is declining, though there are a large
number of marine natural products yet to be explored. This may indicate that the research
level of bioactivity is not keeping up with the discovery of new compounds. Thus, the research
tools and methods for finding bioactivity need to be improved. The first improvement is
about methods of spectral and bioactivity-guided separation and purification of marine-
derived secondary metabolites, which combine the discovery of new compounds. These
improvements in technology are dependent upon the automation in spectroscopy, which
also allows the study of the functions of new compounds extracted from the target marine
organisms. Second, for the discovery of new lead compounds and artificial intelligence for
drug development evolved to a more mechanistic approach that targets specific molecular
lesions. Combined with high-throughput screening through a large number of drug targets,
bioactivity research against various life-threatening diseases will be effective in revealing
the potentially useful biological properties of marine natural products. Furthermore, the
discovery of new bioactive compounds from marine metabolites will form the basis for new
drug leads. Thus, the new compounds will absolutely compose an abundant resource for
future bioactivity research and drug development. Various medicinal and biomedical products
from marine flora and fauna provide a myriad of benefits for human health and multiple
life-threatening diseases, and therefore, are the attractive options for the food and
pharmaceutical industry. The increasing interest in marine-based functional food ingredients
and nutraceutical formulations in the last decade along with increased number of patents
filed/granted have appropriately demonstrated the possibilities of bioactive from marine
organisms to maintain and improve human health and well-being.
The present ICAR Winter School on "Recent advances in bioactive compounds from
marine organisms and development of high-value products for health management" is
designed to acquaint the participants with the advances in marine bioactive compounds
with emphasis on the latest technologies on isolation and characterization of marine natural
products of pharmaceutical importance. The course is planned in such a way that it covers
both theoretical and practical aspect of recent advances in bioactive compounds from marine
organisms. This programme will strengthen the knowledge of participants with regard to
the general and advanced methods of isolation procedures by chromatography, and their
characterization by advanced spectroscopic experiments aspects.
I wish to thank the Education Division of Indian Council of Agricultural Research for
giving us an opportunity to organize this ICAR Winter School. We are grateful to Dr. A.
Gopalakrishnan, Director, ICAR-Central Marine Fisheries Research Institute, for his guidance,
continuous interest in the course and providing all necessary facilities. I am highly obliged
to Dr. P. Vijayagopal, Head, Marine Biotechnology Division for his guidance and support for
the programme. All the scientists of Marine Biotechnology Division, technical staff, supporting
staff and research scholars supported us in organizing the ICAR Winter School. I recall with
gratitude the marvellous effort and help in preparing this manual by Minju Joy, Research
Scholar of Marine Biotechnology Division. I take this opportunity to thank all the faculty
members who have devoted their valuable time and contributed material for the preparation
of the manual. I am confident that the Course Manual would aid the participants to enhance
their knowledge and competence in the area of marine bioactive compounds and their
applications for the development of high-value products for health management.
Kajal Chakraborty
January, 2018 Course Director
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Earth is a blue planet; oceans cover 70% of its surface, and in terms of phyla, the diversity
of the oceans is about double that of the land. Environments such as the deep sea floor,
once thought barren, are now known to be equally or more biologically diverse than tropical
rainforests. It has been known for at least 40 years that microorganisms could be recovered
from the sea. An impressive number of modern drugs have been isolated from
microorganisms, mainly based on their use in traditional medicine. In the past century,
however, an increasing role has been played by microorganisms in the production of
antibiotics and other drugs (Fenical, 1993). The importance of terrestrial bacteria and fungi
as sources of valuable bioactive metabolites is very well established for more than half a
century. As a result, over 120 of the most important medicines (penicillins, cyclosporin A,
adriamycine, etc.) in use today are obtained from terrestrial microorganisms (Alanis, 2005).
For more than two decades, there has been an ongoing quest to discover new drugs from
the sea. Most efforts have been directed towards chemical studies of marine invertebrates
(Chin et al., 2006). Although these studies have indeed proven that marine invertebrates are
an important source of new biomedical leads, a fact well demonstrated by the number of
compounds currently in clinical trials, it has proven notoriously difficult to obtain adequate,
reliable supplies of these compounds from nature. Because of these problems, a new avenue
of study focusing on marine microorganisms has been gaining considerable attention
(Faulkner, 2002). At first sight thus, the expectable enormous biodiversity of marine
microorganisms might have been the reason for the interest in their study. Although marine
microorganisms are not well defined taxonomically, preliminary studies indicate that the
wealth of microbial diversity in the world’s oceans, make this a promising frontier for the
discovery of new medicines (Blunt et al., 2004). Marine bacteria are most generally defined
by their requirements of seawater, or more specifically sodium for growth. In the case of
marine fungi, which in general do not display specific ion requirements, obligate marine
species are generally considered to be those that grow and sporulate exclusively in a marine
habitat. Although such definitions can prove useful, they tend to select for a subset of the
microorganisms that can be isolated from any one environment. This problem is compounded
in the case of near - shore or estuarine samples where a large percentage of the resident
microbes are adapted to varying degrees of marine exposure. For the purpose of microbial
drug discovery, it seems only logical to study all microbes that can be isolated from the
marine environment. Based on the species studied, most of the new compounds reported
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from marine microorganisms were obtained from
species that can, in principle, be isolated from both
land and sea. Although these facultative marine
species are clearly a good source of novel metabolites,
their ecological roles and degrees of adaptation to
the marine environment is largely unknown. Screening
of marine bacteria isolated from the surface of marine
algae and invertebrates has shown that a high
percentage produce antimicrobial metabolites. Marine
microbial floras have an unrivalled capacity to
synthesize bioactive secondary metabolites with a
wide spectrum of bioactivities. Historically,
microorganisms have provided the source for the
majority of the drugs in use today. As new chemical
entities are likely to be discovered from novel
microbes, marine microorganisms are a likely target
for improved technological platforms in the search
and discovery of novel bioactive compounds. The first
antibiotic from marine bacterium was identified and
characterized in 1966 (Burkholder et al., 1966). In
addition, bacteria in biofilms formed on the surface
of marine organisms have been documented to
contain a high proportion of antibiotic producing
bacteria than some other marine environment (Lemos
et al., 1985; Anand et al., 2006). Marine epiphytic bacteria, associated with nutrient rich algal
surfaces and invertebrates, have also been shown to produce antibacterial secondary
metabolites, which inhibit the settlement of potential competitors (Bernan et al., 1997). A
number of surface associated marine bacteria have also been found to produce antibiotics
(Hans et al., 2004). A Bacillus sp isolated from a marine worm in Papua New Guinea produced
a novel cyclic decapeptide antibiotic, loloatin B, which inhibit growth of MRSA (methicillin
resistant Staphylococcus aureus) and VRE (Vancomycin resistant Enterococcus) (Gerard et al.,
1999). The marine bacterium Alteromonas rava was found to produce a new antibiotic
thiomarinol (Shiozawa et al., 1993). Antibiotics from marine microorganisms have been
reported, including loloatins from Bacillus. Agrochelin and sesbanimides from Agrobacterium
(Acebal et al., 1999), pelagiomicins from Pelagiobacter variabilis (Imamura 1997), pyrones
from Pseudomonas (Singh et al., 2003). Screening of seaweed and invertebrate-associated
bacteria has shown their bioactivities (Chakraborty et al., 2010), and that over 25% of these
isolates can produce compounds capable of killing methicillin resistant Staphylococcus aureus
Scehmatic representation of Biospectnig
antibacterial molecules from microbial
flora
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(MRSA) and vancomycin resistant Enterococcus (VRE; Mearns-Spragg et al., 1997). This is a
much higher proportion than found with free-living or soil-associated bacteria.
ANTIMICROBIALS FROM MICROBES, A BRIEF HISTORY
It has been argued that because of the high dilution effect of seawater, marine-derived
bioactive compounds may have evolved great potency. This theory was supported in 2004
with the report of a first-in-class antimicrobial compound, was described from a marine
isolate Verrucosispora. Renewed interest in marine microorganisms and their ability to
produce antimicrobials has resulted in numerous reports of novel antimicrobial compounds.
The period of antimicrobial drug discovery from the early 1940s to the 1960s is referred to
as the Golden Age. During this time, the industrialization of penicillin production created
the expertise and facilities to make significant quantities of antimicrobial compounds by
fermentation. The clinical use of antibiotics heralded a health care miracle; deaths due to
bacterial infections were significantly reduced, resulting in increases in life expectancy. The
majority of compounds that were discovered during this period were isolated from soil
bacteria, most notably the filamentous Actinobacteria. Microorganisms are a prolific source
of structurally diverse bioactive metabolites and have yielded some of the most important
products of the pharmaceutical industry. Microbial secondary metabolites are now being
used for applications other than antibacterial, antifungal and antiviral infections. It was
during 1928s when Alexander Fleming (Fleming, 1929) began the microbial drug era when
he discovered in a Petri dish seeded with Staphylococcus aureus that a compound (penicillin)
produced by a fungus/mold killed the bacteria. Later, penicillin was isolated as a yellow
powder and used as a potent antibacterial compound during the Second World War.
Following this extraordinary discovery be Flemming, the antibiotics chloramphenicol and
streptomycin, were isolated. Naturally occurring antibiotics are produced by fermentation,
an old technique that can be traced back almost 8000 years. Owing to technical improvements
in screening programs, and separation and isolation techniques, the number of natural
compounds discovered exceeds 1 million (Ecker et al., 2005). Among them, 50-60% are
produced by plants (alkaloids, flavonoids, terpenoids, steroids, carbohydrates, etc.) and 5%
have a microbial origin. Of all the reported natural products, approximately 20–25% show
biological activity, and of these approximately 10% have been obtained from microbes.
Furthermore, from the 22 500 biologically active compounds that have been obtained so
far from microbes, 45% are produced by bacteria or bacteria-like microbes, 38% by fungi
and 17% by others (Berdy, 2005). The increasing role of microorganisms in the production
of antibiotics and other drugs for treatment of serious diseases has been dramatic. However,
the development of resistance in microbes to various life-thretening diseases and in
aquaculture has become a major problem and requires much research effort to combat it.
The emergence of antibiotic resistance in 1970s coincided with high rediscovery rate of the
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major antimicrobial classes; the low-hanging fruit had apparently all been picked.
Antimicrobial development after the Golden Age was characterized by semi-synthetic
modifications of compounds that were already clinically proven. The poor antimicrobial
discovery rate from microbes, coupled with the availability of chemically synthesized small
molecule libraries, led to the abandonment of microbial screening programmes in the majority
of pharmaceutical companies. To date, small chemical libraries have failed to deliver a new
antimicrobial compound to the clinic, prompting many to speculate that the withdrawal of
microbial screening was premature, exacerbating the threat of antibiotic resistant bacteria.
MICROBIAL NATURAL PRODUCTS
Microbial natural products that have reached the market without any chemical
modifications are a testimony to the remarkable ability of microorganisms to produce drug-
like small molecules. Although still in clinical trails, a feature example of this is salinosporamide
A (NPI-0052), a novel anticancer agent found in the exploration of new marine environments
(Fenical et al., 2009). In 2008, over 1000 marine natural products were reported (Blunt et al.,
2010). However, out of 19 microbial-derived drugs reported in 2008, no natural products
from marine microbes were present, signifying the novelty of their systematic exploration
(Ganesan, 2008). Currently, >30 compounds of marine microbial origin are in clinical or
preclinical studies for the treatment of different types of cancer (Simmons et al., 2005)
clearly demonstrating that marine microorganisms have become an essential resource in
the discovery of new antibiotic leads. The evolution of marine microbial natural product
collections and development of high-throughput screening methods have attracted
researchers to the use of natural product libraries in drug discovery. These libraries include
subsections of crude extracts, pre-fractionated extracts (automated HPLC-MS fractionation)
and purified natural products. A research group in Ireland has developed a two-dimensional
chromatographic strategy that includes a protocol to generate purified marine natural
product libraries that are accurately characterized by mass during production to expedite
dereplication of known compounds and identification of novel chemotypes. Although the
biosynthetic and regulative crosstalk of secondary metabolite biosynthesis is complex within
and between microorganisms, all levels can be influenced by imitating natural environmental
changes. Development and testing of new culture media for the maximum expression of
secondary metabolites is important as chemical diversity in the construction process of a
marine natural products library.
An optimization of ‘one strain, many active compounds’ can be used together with
‘fingerprint’ methods (HPLC and nuclear magnetic resonance) including tandem analytical
techniques such as MS/MS, GC-EI/MS, HPLC-SPE-NMR, LC-MS-MS and LC-NMR for the
optimization/selection of culture media for high-throughput fermentation of novel strains.
Tormo et al., (2003) developed a method for the selection of production media for bacterial
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strains based on their metabolite HPLC profiles, that yielded the highest metabolite diversity
and least overlapping HPLC profiles were selected for large-scale fermentation. Targeted
high-throughput screening methods are important for the speed and accuracy of
identification of novel antimicrobials. From these evaluation models, many crude extracts
or purified compounds were obtained as positive hits. In addition for evaluation purposes,
it is worthy to note that these screening assays also provide mode of action hypothesis
from the crude extracts.
ANTIBACTERIAL MOLECULES FROM NATURAL SOURCES
Drugs of natural origin have been classified as (i) original natural products, (ii) products
derived or chemically synthesized from natural products or (iii) synthetic products based on
natural product structures. Evidence of the importance of natural products in the discovery
of leads for the development of drugs for the treatment of human diseases and aquaculture
are provided by the fact that close to half of the best selling pharmaceuticals and antibiotics
in 1990-2000 were either natural products or their derivatives (Cragg et al., 1997). In this
regard, of the 25 top-selling drugs reported in 1997, 42% were natural products or their
derivatives and of these, 67% were antibiotics. Today, the structures of around 140 000
secondary metabolites have been elucidated. Applications of chemically synthesized natural
metabolites include the use of a natural product derived from plant salicyclic acid derivatives
present in wintergreen and meadowsweet to relieve pain and suffering. Synthetic salicylates
were produced initially by Bayer in 1874, and later in 1897, Arthur Eichengrun at Bayer
discovered that an acetyl derivative (aspirin), reduced acidity, bad taste and stomach irritation.
These plant-based systems continue to play an essential role in health care, and it has been
estimated by the World Health Organization (WHO) that approximately 80% of the world’s
inhabitants rely mainly on traditional medicines for their primary health care (Farnsworth et
al., 1985). The alkaloid quinine, the active constituent of Cinchona succirubra, has been
known for centuries by South American Indians to control malaria. During the twentieth
century, massive programs to synthesize quinoline derivatives, based on the quinine
prototype, were carried out. The first of the new quinolones to be used clinically as an
antibacterial agent was nalidixic acid (Topliss et al., 2002). The compound 7-chloro-1,4-
dihydro-1-ethyl-4-oxoquinolone-3-carboxylic acid was obtained as a side product during
purification of chloroquine and found to have antibacterial activity against Gram-negative
bacteria and was shown to be an inhibitor of DNA gyrase. Its discovery led to a whole series
of synthetic quinolone and fluoroquinolone antibiotics (pefloxacin, norfloxacin, ciprofloxacin,
levofloxacin, ofloxacin, lomefloxacin, sparfloxacin, etc), which have been very successful in
medicine and have achieved major commercial success. Secondary metabolites have exerted
a major impact on the control of infectious diseases and other medical conditions, and the
development of pharmaceutical industry. Their use has contributed to an increase in the
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average life expectancy in the world. In 2000, the market for major antiinfectives from bacteria
and other natural sources was US$55 billion and in 2007 it was US$66 billion.
Various classes of antibiotics/drugs from microbial flora (upto 2000) (Barber, 2001).
Sl. No. Antibiotics/drugs Market share (US billion $)
1 Antiviral compounds 10.2
2 Penicillins 8.2
3 Cephalopsporins 9.9
4 Beta lactam antibiotics 1.5
5 Quinolines 6.4
6 Other antibacterials 6.0
7 Tetracyclines 1.5
Two antivirals that are chemically synthesized today were originally isolated from marine
organisms. They are acyclovir (active against the herpes virus by inhibition and inactivation
of DNA polymerase) and cytarabine (active against non-Hodgkin’s lymphoma). Both
compounds are nucleoside analog drugs, originally isolated from sponges (Rayl, 1999).
Other antiviral applications of natural compounds are related to human immunodeficiency
virus (HIV) treatment. Furthermore, reports have been published on natural product inhibitors
of HIV integrase obtained from among the marine ascidian alkaloids; that is, the lamellarins
(produced by the mollusk Lamellaria sp.), and from terrestrial plants (Baccharis genistelloides
and Achyrocline satureioides). The most consistent anti-HIVactivity was observed with extracts
prepared from several Baccharis species (Robinson et al., 1996).
ANTIBIOTICS FROM MARINE MICROBES
During recent decades, we have seen an increasing number of reports on the progressive
development of bacterial resistance to almost all available antimicrobial agents. In the 1970s,
the major problem was the multidrug resistance of Gram-negative bacteria, but later in the
1980s the Gram-positive bacteria became important, including methicillin-resistant
staphylococci, penicillin-resistant pneumococci and vancomycin-resistant enterococci
(Moellering, 1998). In the past, the solution to the problem has depended primarily on the
development of novel antimicrobial agents. However, the number of new classes of
antimicrobial agents being developed has decreased dramatically in recent years. The
conventionally used antibiotics/drugs become resistant to most of the natural antimicrobial
agents that have been developed over the past 50 years (Hancock, 2007) thereby limiting
the effectiveness of current antimicrobial drugs. In 2004, more than 70% of pathogenic
bacteria were estimated to be resistant to at least one of the currently available antibiotics
(Katz et al 2006). The so-called ‘superbugs’ (organisms that are resistant to most of the
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clinically used antibiotics) are emerging at a rapid rate. S. aureus, which is resistant to
methicillin, is responsible for many cases of infections each year (Balaban et al., 2005). The
incidence of multidrug-resistant pathogenic bacteria is increasing. The Infectious Disease
Society of America (IDSA) reported in 2004 that in US hospitals alone, around 2 million
people acquire bacterial infections per year (dedicated website: http://www.idsociety.org/
Content.aspx). There are also other examples of Gram-positive (Enterococcus and
Streptococcus) and Gram-negative pathogens (Klebsiella, Escherichia, Enterobacter, Serratia,
Citrobacter, Salmonella and Pseudomonas) (Cragg and Newman, 2001). Among them,
Pseudomonas aeruginosa accounts for almost 80% of these opportunistic infections. They
represent a serious problem in patients hospitalized with cancer, cystic fibrosis and burns,
causing death in 50% of cases. Other infections caused by Pseudomonas species include
endocarditis, pneumonia and infections of the urinary tract, central nervous system, wounds,
eyes, ears, skin and musculoskeletal system (Levin and Bonten, 2004). In addition to the
antibiotic-resistance problem, new families of anti-infective compounds are needed to enter
the marketplace at regular intervals to tackle the new diseases caused by evolving pathogens.
At least 30 new diseases emerged in the 1980-2000s and they are growing in incidence.
Emerging infectious organisms often encounter hosts with no prior exposure to them and
thus represent a novel challenge to the host’s immune system. Several viruses responsible
for human epidemics have made a transition from animal host to humans and are now
transmitted from human to human. HIV, responsible for the acquired immunodeficiency
syndrome (AIDS) epidemic, is one example. Although it has not been proven, it is suspected
that severe acute respiratory syndrome (SARS), caused by the SARS coronavirus, and also
evolved from a different species (Kremer et al., 2000). One additional reason for developing
new antibiotics is related to their own toxicity. As with other therapeutic agents, the use of
antibiotics may also cause side effects in patients. Some side effects are more severe and,
depending on the antibiotic, may disrupt the hearing function (aminoglycosides), kidneys
(aminoglycosides and polypeptides) or liver (rifampin).
NEW MOLECULES AS A SOLUTION TOWARDS MULTIRESISTANT ANTIBIOTIC AND
DRUG MOLECULES
In recent times, several scientific groups are making concerted efforts to find novel
antimicrobial agents as a solution towards multiresistant antibiotic and drug molecules.
Novel glycylcyclines (modified Tetracyclines) developed to treat tetracycline-resistant bacteria.
These show potent activity against a broad spectrum of Gram-positive and Gram-negative
bacteria, including strains that carry the two major tetracycline-resistance determinants,
involving efflux and ribosomal protection. Two of the glycylcyline derivatives, DMG-MINO
and DMG-DMDOT have been tested against a large number of clinical pathogens isolated
from various sources. The spectrum of activity of these compounds includes organisms
196 Recent advances in bioactive compounds from marine organisms and development of high value products
Marine microbes as a source of antimicrobial compounds
with resistance to antibiotics other than tetracyclines; for example, methicillin-resistant
staphylococci, penicillin-resistant S. pneumoniae and vancomycin-resistant enterococci (Sum,
2006). Tigecycline was approved by the FDA in 2005 as an injectable antibiotic (Bacque et
al., 2005). A new glycopeptide antibiotic, teicoplanin, was developed against infections with
resistant Gram-positive bacteria, especially bacteria resistant to the glycopeptide vancomycin.
In another instance, the approach involved the redesign of a mixture of two compounds,
called streptogramin, into a new mixture, called pristinamycin, to allow administration of
the drug parenterally and in higher doses than the earlier oral preparation (Bacque et al.,
2005). The two components of streptogramin, quinupristin and dalfopristin, were chemically
modified to allow intravenous administration. The new combination, pristinamycin, was
approved by the FDA for use against infections caused by vancomycin-resistant Enterococcus
faecium. Among the novel class of antimicrobial agents used in treating resistance to Gram-
positive infections, we can also mention the cyclic lipopeptide antibiotic daptomycin
produced by Streptomyces roseosporus. This compound was approved in 2003 by the FDA
for skin infections resulting from complications following surgery, diabetic foot ulcers and
burns (LaPlante et al., 2004). Telithromycin, a macrolide antibiotic, is the first orally active
compound of a new family of antibacterials named the ketolides. It shows potent activity
against pathogens implicated in community acquired respiratory tract infections, irrespective
of their â-lactam, macrolide or fluoroquinolone susceptibility (Leclercq, 2001).
AQUACULTURE GRADE ANTIMICROBIAL CHEMICALS FROM MARINE MICROBES
Disease caused by bacterial pathogens has been widely recognized as a major cause
of economic loss in many commercially cultured fish and shellfish species in India, with
mortality of larval stages in hatcheries and the growing stages in different mariculture systems.
Pathogenic vibrios are involved in significant mortalities in the larviculture and growout
phases of famed finfish and shellfishes. In an attempt to control the proliferation of
pathogenic vibrios, the prophylactic and therapeutic use of antibiotics has been practiced
in commercial hatcheries, creating more serious problem of antibiotic resistance among
the microflora in the environment. With safety concerns about synthetic antibiotics,
considerable interest has arisen in finding alternative natural sources (Gomez-Gil et al.,
2000). Screening and development of aquaculture-grade chemicals from bacterial flora could
be a highly promising approach to produce these bioactive moleules. Members of the
genus Pseudomonas and Bacillus either free living or associated with marine flora are common
beneficial bacterial candidates, and are known to produce a wide range of secondary
metabolites (Raaijmakers et al., 1997) inhibiting a wide range of pathogenic bacteria
(Rengpipat et al., 1998). The metabolites 6-oxo-de-O-methyllasiodiplodin, (E)-9-etheno-
lasiodiplodin, lasiodiplodin, de-O-methyllasiodiplodin, and 5-hydroxy-de-O-
methyllasiodiplodin, were isolated from the mycelium extracts of a microbe obtained from
Recent advances in bioactive compounds from marine organisms and development of high value products
Marine microbes as a source of antimicrobial compounds
197
South China Sea (Yang et al., 2006). Bioactive compounds were isolated from a marine
bacterium Bacillus circulans (Chakraborty et al., 2010). Labda-14-ene-3a,8a-diol and labda-
14-ene-8a-hydroxy-3-one were found to be inhibitory to the growth of Vibrio
parahaemolyticus with minimum inhibitory concentrations of 30-40 µg/mL (Chakraborty et
al., 2010), and their structures have been elucidated by 1H NMR and 13C NMR spectra,
including 2D NMR. Several bacterial flora were isolated from marine ecosystem (Bacillus
subtilis, B. amyloliquifaciens, Pseudomonas putida and P. aeroginosa) with potential activities
(> 20 mm inhibition zone) against pathogenic Vibrios (Chakraborty et al., 2010). The
antibacterial component in the CHCl3 fraction of P. aerogenosa was found to be N-substituted
methyl-octahydro-1-phenazinecarboxylate. The other important antibacterial molecules were
found to be propyl 2-oxoacetate and phenethyl 2-oxoacetate.
About 4530 bacterial isolates were purified from seaweeds and sediments, and 23 isolates
(B. subtilis MTCC 10402, 10403 and 10407, B. amyloliquifaciens 10456, P. putida MTCC 10458,
P. aeroginosa MTCC 10610) were found to be potential against pathogenic Vibrios. N-
substituted phenazinecarboxylate, propyl/phenethyl 2-oxoacetates were the major
antibacterial molecules in bacteria.
CONCLUSIONS
The ability of marine microorganisms to produce novel antimicrobial compounds has
been well demonstrated, and clearly they have a future role in the fight against antibiotic-
resistant pathogens. Ongoing research efforts to isolate and screen new marine
microorganism species should be accompanied by efforts to understand their ecology.
Extensive culture-dependent and -independent surveys of marine microorganisms should
be prioritized to determine the extent to which marine diversity differs, e.g. is the isolation
of rare microorganisms’ genera from the sea merely due to the fact that terrestrial-to-sea
input skews the species distribution. The isolation of seawater-obligate microorganisms
has proved that marine adaptation has occurred in this lineage, but so far this property has
only been identified at the genus and species level, an indication that marine adaptation is
a comparatively recent evolutionary event. If such adaptation is rare within the
microorganisms, it is reasonable to expect that seawater-obligate strains will represent species
that have no terrestrial counterparts, and thus they are unlikely to have been previously
screened for antimicrobial compounds. This raises the intriguing possibility that there are
antimicrobial compounds unique to marine species. Whole-genome analysis of the genus
Salinispora indicates hat differences in secondary metabolite biosynthetic genes may be a
driver of speciation, supporting the hypothesis that new species will produce new
compounds. Further analysis is needed to determine whether this property will hold as
more species are described. Finally, if antimicrobial compounds are to make it from the
ocean to the clinic, big pharma must re-engage in drug discovery from microbes. Currently,
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small pharmaceutical and biotechnology companies have been, or are currently engaged in
antimicrobial discovery from marine microorganisms
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